Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.58 |
| ▸ | CDK2 | P24941 | 5/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.53 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 5/20 | 0.49 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | CDK7 | P50613 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333695 | 0.92 | PDGFRB (0.55) | RETCDK2TLK2KDRFGFR1 | |
| SCHEMBL6326979 | 0.88 | ALK (0.50) | RETPDPK1KDRCSNK1DMAPK1 | |
| SCHEMBL6328615 | 0.87 | KDR (0.49) | RETPDPK1KDRCSNK1DMAPK1 | |
| SCHEMBL6328765 | 0.86 | RET (0.56) | RETCDK2KDRFGFR1PDGFRB | |
| SCHEMBL6326803 | 0.86 | RET (0.56) | RETCDK2KDRFGFR1PDGFRB | |
| SCHEMBL6327010 | 0.86 | ALK (0.59) | RETCDK2CCNE1TLK2PDPK1 | |
| SCHEMBL6328965 | 0.85 | KDR (0.58) | RETPDPK1KDRCSNK1DMAPK1 | |
| SCHEMBL6333700 | 0.82 | CDK2 (0.52) | RETCDK2CCNE1KDRMAPK1 | |
| SCHEMBL6333460 | 0.81 | AURKA (0.53) | RETCDK2KDRCSNK1DFGFR1 | |
| SCHEMBL6328862 | 0.80 | KDR (0.66) | RETPDPK1KDRCSNK1DFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032871-A1 | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2005-02-10 | — | — | US | claimed |
| US-20050032871-A1 | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032871-A1 | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors | MAP3K20, CDK20, STK10 | RET 219/4885CDK2 42/4885CCNE1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.